Articles tagged with Breast Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A Concordia-led research team found that Lithocholic acid (LCA) selectively kills cancer cells while sparing healthy ones. LCA targets cancer cell sensors, triggering mitochondrial self-destruction and bringing the cell down.
Researchers discovered an agent, PEDF, that suppresses brain metastatic activity and shields the brain from tumor-induced damage. This finding represents a significant step forward in managing brain metastases, a major challenge in cancer treatment.
Research suggests that breast cancer survivors who practice MBSR experience improved mood, reduced stress markers, and increased mindfulness. The study highlights the potential benefits of this non-pharmaceutical approach as a complement to traditional treatments.
A Wayne State University researcher is studying the signaling process that triggers breast cancer transformation. The objective of his three-year study is to evaluate the potential roles of two small proteins in breast cancer progression.
Researchers found that patients with initial metastatic breast cancer tend to be older and have lower-grade tumors, while those with early relapse after treatment are younger and have more aggressive cancer. The study emphasizes the importance of increasing awareness about breast care and the need for novel therapeutic strategies to im...
Researchers at Penn developed a new MRI contrast agent that targets acidic environments of tumors, improving diagnosis accuracy. The coating technology allows the particles to be neutral near healthy tissue but become ionized in low pH, attracting them to tumor sites.
Research reveals that cancer cells use a positive feedback loop involving c-MYC and SIRT1 to drive continuous cell division and tumor growth. This mechanism undermines normal cell regulation, leading to uncontrolled proliferation and treatment resistance in certain types of cancer.
A study by McMaster researchers found consistent evidence that hormone replacement therapy is associated with an increased risk of breast cancer globally. The research suggests that decreased HRT use after the WHI trial led to a decline in breast cancer incidence in many countries.
Researchers at Ohio State University found that normal cells in tumors can enhance cancer cell growth after losing a tumor suppressor gene called Pten. The study suggests interrupting signals between normal cells and cancer cells as a new approach to treating breast cancer.
Research reveals that women at risk for breast cancer are also at a higher risk for heart disease due to mutations in the BRCA1 and BRCA2 genes. The study found that these genes regulate heart function and can lead to increased mortality rates after a heart attack.
A novel study led by UCSF found that mammograms detect slower-growing breast cancers in women over 50, increasing the likelihood of good prognosis without treatment. The research provides a basis for integrating molecular profiling to avoid overtreatment and improve care.
Researchers have discovered a microRNA, miR-520, that suppresses NFkappaB and TGF-b signaling pathways in breast cancer cells. This finding suggests that miR-520 may act as a tumor suppressor and could lead to new treatment options for ER-negative breast cancer.
A study found APBIb use increased from 0.4% to 6.6% between 2000 and 2007, with wide regional disparities and racial/ethnic differences in utilization. The authors suggest unwarranted variation in practice may be present, highlighting the need for further research on APBI effectiveness.
Researchers have developed a vaccine that successfully attacks breast cancer in mice, with implications for treating ovarian, colorectal and pancreatic cancer. The vaccine targets MUC1, a protein found on over 90% of human breast and pancreatic cancer cases.
A new test developed by QUT PhD student Helen McCosker can predict the likelihood of breast cancer growth, dormancy, or spread to other organs. The test analyzes tissue surrounding cancer cells and offers personalized treatment plans for patients.
A new analysis found that breast cancer survivors may experience mental abilities problems several years after treatment, regardless of therapy type. Chemotherapy was linked to persistent cognitive issues, while radiation also caused similar problems in some cases.
Scientists developed a vaccine that reduces tumors by 80% in mouse models of breast and pancreatic cancer. The vaccine uses a unique carbohydrate signature to train the immune system to target cancer cells.
Researchers found that between 1992 and 2005, the percentage of patients who had multiple imaging visits nearly quadrupled, from 4.9% to 19.4%. A single imaging visit increasingly includes multiple types of imaging, with the rate rising from 4.3% to 27.1%.
Women with newly diagnosed inflammatory breast cancer who have stray tumor cells in their blood should receive aggressive treatment, regardless of imaging results. Researchers found no correlation between circulating tumor cells and survival rates in these patients.
Researchers found that loss of the retinoblastoma tumor suppressor gene (RB) in triple negative breast cancer patients is linked to improved survival rates. This discovery could lead to personalized treatment approaches for these patients.
A new study by Northwestern University finds that joint pain is the most common reason for women to stop taking aromatase inhibitors, a common breast cancer medication. The research also highlights a gap between clinicians' reported side effects and women's actual experiences.
A new study found that women with BRCA1 or BRCA2 mutations inherited from their fathers tend to be diagnosed with breast cancer a decade earlier than those who inherit the genes from their mothers. The research analyzed 130 patients and discovered significant differences in age of diagnosis based on parent-of-origin effects.
Researchers found that restricting carbs two days a week leads to greater weight loss and improved insulin levels compared to daily calorie restriction. This approach may be a more effective way to prevent breast cancer and other diseases, according to the study.
Researchers found that increased starch intake was associated with a greater risk of breast cancer recurrence in women. Women who increased their starch intake over one year were at a higher risk for recurring, with changes in starch intake accounting for 48% of the change in carbohydrate intake.
Cancer incidence rates have increased while deaths have decreased in Australia over the past quarter century. The study found that Indigenous Australians face higher death rates due to disparities in cancer diagnoses, treatments, and other illnesses.
Women who use breast-enhancing dietary supplements containing zearalenone (ZEN) may be increasing their risk of breast cancer. The review highlights concerns over ZEN's effects on the human reproductive system and breast cancer, as well as its links to premature puberty and infertility.
Researchers have developed ways to exploit the addictions of cancers to kill them without harming normal tissues. The study identified SUMOylation as a key biochemical process involved in coping with cancer cell stress, and inhibiting this enzyme may be a therapeutic strategy for myc-driven cancers.
Only about one-third of women undergo immediate reconstructive breast surgery after mastectomy, which improves psychological well-being and quality of life. Factors such as age, insurance status, and hospital location influence the likelihood of reconstruction, highlighting the need for increased access to this procedure.
Researchers precisely measured protein levels in 1,400 tumor biopsies and found no correlation between HER3 protein levels and Herceptin treatment outcome. The study suggests that single biomarkers like HER3 are not predictive of benefit from Herceptin treatment.
A large study showed that obese patients have poorer long-term outcomes than normal-weight patients when not treated with trastuzumab. Adding trastuzumab to treatment may potentially equalize disease-free survival rates among all patient groups.
Researchers found correlations between MRI measures and histopathological markers of breast cancer, suggesting the potential for MRI in predicting disease prognosis and guiding targeted therapies. The study's findings could lead to improved understanding of breast cancer biology and more accurate treatment planning.
Women with BRCA1 or BRCA2 mutations are at high risk for developing contralateral breast cancer, and certain subgroups are more susceptible based on age and first tumor status. The study found that carriers have a 17.9% 10-year risk, while non-carriers have a 6.0% risk.
A phase II multi-institutional study of women at increased risk for breast cancer evaluated the safety and efficacy of exemestane over two years, showing steady decreases in 'good' cholesterol levels. While this effect may prove significant for women at high risk for heart disease, its clinical significance remains unknown.
Whole-genome sequencing reveals activation of targets for new treatment strategies, including MEK/AKT inhibitors for metastatic triple negative breast cancers. The study's results indicate potential for improved treatment options for nearly 20% of breast cancers that do not respond to targeted therapies.
A study by Mayo Clinic researchers found that obese patients with HER2-positive breast cancer had poorer outcomes, larger tumors, and were more likely to have lymph node involvement compared to normal-weight patients. The study's lead author notes that excess body weight may affect treatment outcome for this subtype of breast cancer.
Research found obesity associated with shorter time to recurrence and disease-free survival in early-stage breast cancer. However, treatment with endocrine therapy showed a protective effect against obesity-related poor outcomes.
Researchers found that a combination of anti-estrogen drugs anastrozole and fulvestrant can lengthen the lives of post-menopausal women with hormone receptor-positive metastatic breast cancer. The therapy also showed promise in patients who had not previously received tamoxifen therapy.
A new study by researchers from the University of Pennsylvania School of Medicine found that contralateral prophylactic mastectomy (CPM) provides only a modest increase in life expectancy among women with unilateral breast cancer. The surgery may actually reduce quality-adjusted life expectancy for patients without hereditary factors.
A German study found no improvement in disease-free survival among breast cancer patients treated with dose-dense chemotherapy and oral ibandronate. The results contradict previous studies, which showed benefits in postmenopausal patients receiving zoledronic acid or endocrine treatment.
Researchers found that adding pertuzumab to trastuzumab and docetaxel chemotherapy extended progression-free survival by 6.1 months, with a 38% reduction in risk for progression. The three-drug combination was also remarkably safe and well-tolerated.
Researchers found a median progression-free interval of 7.4 months for patients treated with exemestane and everolimus, compared to 3.2 months for those receiving placebo. Clinical benefit rates were also higher in the combined treatment group, with 50.5% experiencing complete response or stable disease.
The addition of zoledronic acid to adjuvant endocrine therapy increased bone mineral density and reduced disease recurrence among postmenopausal women with early hormone receptor-positive breast cancer. Immediate zoledronic acid use also improved survival outcomes, particularly in women who were truly menopausal at diagnosis.
Breast cancer mortality is higher in Hispanic women compared to non-Hispanic white women, with a 20% increased risk of death. The ethnic disparity may be attributed to tumor phenotypes less responsive to chemotherapy, which affects long-term survival rates.
A recent study found that clodronate had a low incidence of adverse events and toxicity among patients with breast cancer. The treatment modestly reduced the incidence of distant metastases in postmenopausal women, with a relative reduction of 9% compared to placebo.
Researchers confirm zoledronic acid's continued effectiveness in reducing breast cancer recurrences and improving survivorship rates among premenopausal women with estrogen receptor-positive breast cancer. The study found a 28% reduced risk for recurrence and a 36% reduction in mortality risk, with no toxic side effects.
The addition of bevacizumab to trastuzumab and docetaxel improved progression-free survival in patients with HER2-positive, locally recurrent/metastatic breast cancer. Median progression-free survival increased by 2.8-2.9 months with bevacizumab.
Researchers found that combining everolimus and exemestane significantly improved progression-free survival by 4.2 months, with a clinical benefit rate of 50.5% in the combination arm. The study suggests a new approach for treating hormone-resistant breast cancer, which may change treatment practices.
A new study found that taking two breast cancer medications together, anastrozole and fulvestrant, significantly extended the lives of women with metastatic breast cancer. Women who received the combination treatment lived over six months longer than those who took the drugs in sequence.
A new triple drug combination has been shown to increase tumour eradication in HER2-positive breast cancer by more than half, with 46% of patients achieving a pathological complete response. The treatment was well-tolerated and did not significantly increase side effects or cardiac risk compared to standard therapy.
Researchers at Tel Aviv University have developed a radioactive wire that destroys tumors from the inside out, creating an immunity against cancer return. This innovative method, called DARTTM, has shown promising results in pre-clinical trials and is now being commercialized for clinical trials.
A retrospective study found that women treated with accelerated partial breast irradiation therapy have a two-fold increased risk for subsequent mastectomy, most likely due to tumor recurrence or local complications. APBI brachytherapy was also associated with higher incidence of acute and late toxicities compared to traditional whole ...
A significant number of women with breast cancer are not receiving guideline-recommended adjuvant treatment. The research found that socioeconomic factors such as poverty, insurance status, and education level significantly contribute to this disparity. Women from high-poverty areas were less likely to receive guideline therapy, highli...
Researchers developed a multigene test to identify high-risk patients with ductal carcinoma in situ (DCIS) and differentiate between lower-risk and more aggressive forms. The DCIS Score algorithm predicts individual risk for recurrence, allowing physicians to provide tailored treatment programs.
A study found significant gene expression patterns among tumor samples that correlated with distant metastatic disease development. These patterns may help personalize treatment and predict which patients are likely to recur early or late.
Research found that diabetes increases breast cancer risk by 37% in women diagnosed within four years of cancer development. Obesity after age 60 also significantly increases the risk, with a 55% increase in breast cancer cases compared to the general population. High and low blood lipids were also associated with different risks.
A research team discovered distinct gene patterns associated with early and late breast cancer recurrences, which could help predict patient outcomes and guide personalized therapy. The findings may enable oncologists to delay or prevent recurrences and reduce excessive treatment for patients who will not recur.
Women treated with brachytherapy experienced a twofold increased risk for losing their breasts compared to those treated with whole-breast irradiation. Brachytherapy also led to nearly a twofold higher risk of postoperative infections and complications, as well as radiation-related side effects.
Researchers found that dopamine injections improved blood flow to tumors, doubling the concentration of an anticancer drug and increasing its effectiveness. Dopamine also normalized the structure of abnormal tumor blood vessels, a condition typically associated with reduced chemotherapy and radiation therapy effectiveness.
Researchers will collect cancer incidence data from 13 Appalachian states to identify differences in relative survival and avoidable death between sub-regions and non-Appalachian areas. The findings will inform the development of effective evidence-based cancer control interventions for the region.
A meta-analysis of 123 randomised trials involving 100,000 women with breast cancer shows that modern chemotherapy regimens reduce breast cancer mortality by around one-third compared to no chemotherapy. The findings suggest that standard 1980s chemotherapy regimens could produce a reduction of almost a quarter in breast cancer mortality.